Loftin Charles D, Trivedi Darshini B, Langenbach Robert
Laboratory of Environmental Carcinogenesis and Mutagenesis, National Institutes of Health, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.
J Clin Invest. 2002 Aug;110(4):549-57. doi: 10.1172/JCI14924.
Preterm delivery is the leading cause of neonatal mortality and contributes significantly to infant morbidity. Classical cyclooxygenase (COX) inhibitors, such as indomethacin, which inhibit both COX-1 and COX-2, are effective for delaying premature labor, but their use is limited by serious complications to the fetus and neonate, including adverse effects on the ductus arteriosus (DA). Using isoform-selective inhibitors, we characterized the roles of the COX isoforms in the initiation of labor and the regulation of fetal and neonatal DA closure in mice. Chronic inhibition of COX-2 during pregnancy (gestation days 15-18) significantly increased neonatal mortality by preventing closure of the DA after birth, whereas acute COX-2 inhibition near the end of term (gestation day 18) constricted the fetal DA. In contrast, the inhibition of COX-1 during pregnancy lacked these prenatal and postnatal adverse effects on the DA and effectively delayed the initiation of full-term labor and LPS-induced preterm labor. These findings suggest that premature fetal DA closure or neonatal patent DA observed following indomethacin tocolysis in women may result from the inhibition of COX-2. Therefore, COX-1-selective inhibitors may provide effective treatment to delay preterm labor with fewer adverse effects on fetal or neonatal health than nonselective or COX-2-selective inhibitors.
早产是新生儿死亡的主要原因,且对婴儿发病有重大影响。经典的环氧化酶(COX)抑制剂,如吲哚美辛,可同时抑制COX-1和COX-2,对延迟早产有效,但其使用因对胎儿和新生儿的严重并发症而受限,包括对动脉导管(DA)的不良影响。我们使用亚型选择性抑制剂,确定了COX亚型在小鼠分娩发动及胎儿和新生儿DA关闭调节中的作用。孕期(妊娠第15 - 18天)慢性抑制COX-2可通过阻止出生后DA关闭而显著增加新生儿死亡率,而在足月临近时(妊娠第18天)急性抑制COX-2可使胎儿DA收缩。相比之下,孕期抑制COX-1对DA没有这些产前和产后的不良影响,并能有效延迟足月分娩发动和脂多糖诱导的早产。这些发现表明,女性使用吲哚美辛进行安胎治疗后观察到的胎儿DA过早关闭或新生儿DA未闭可能是COX-2受抑制所致。因此,与非选择性或COX-2选择性抑制剂相比,COX-1选择性抑制剂可能提供有效的治疗来延迟早产,且对胎儿或新生儿健康的不良影响更少。